Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomy19-norandrostenedione
Identification
- Name
- 19-norandrostenedione
- Accession Number
- DB01434
- Type
- Small Molecule
- Groups
- Experimental, Illicit
- Description
19-Norandrostenedione refers to two steroid isomers that were once marketed as dietary supplements and mainly used by body builders. After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.
In the body 19-norandrostenedione is rapidly metabolized into nandrolone, also known as nortestosterone.
- Structure
Structure for DB01434 (19-norandrostenedione)
- Synonyms
- 4-estrene-3,17-dione
- delta4-Estrene-3,17-dione
- NOR
- External IDs
- NSC-12164
- International/Other Brands
- 19-N-Andro / Bolandione / Proven Pure 19-Norandrostenedione
- Categories
- UNII
- U90987PVU5
- CAS number
- 734-32-7
- Weight
- Average: 272.382
Monoisotopic: 272.177630012 - Chemical Formula
- C18H24O2
- InChI Key
- JRIZOGLBRPZBLQ-QXUSFIETSA-N
- InChI
- InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-16H,2-9H2,1H3/t13-,14+,15+,16-,18-/m0/s1
- IUPAC Name
- (1S,2R,10R,11S,15S)-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-ene-5,14-dione
- SMILES
- [H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Pharmacology
- Indication
The claim that supplemental 19-norandrostenedione has anabolic effects is unsubstantiated.
- Pharmacodynamics
- Not Available
- Mechanism of action
19-Norandrostenedione may be metabolized to 19-nortestosterone in both men and women. 19-Norandrostenedione, also known as nandrolone, is the basic substance of some very popular injectable anabolic steroids, however 19-norandrostenedione is not metabolized to testosterone. Whether or not increases in 19-nortestosterone levels would be sustained long enough by taking 19-norandrostenedione to show an increase in nitrogen retention and muscle strength and mass is unknown.
19-Norandrostenedione has also been shown to bind to androgen receptors with high selectivity. Transactivation of androgen receptor dependent reporter gene expression was 10 times lower than that produced by dihydrotestosterone. [1]
- Absorption
Absorption appears variable, but some absorption does occur.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Specific metabolites of 19-nor-5-androstene-3, 17-dione are 19-nordehydroandrosterone and 19-nordehydroepiandrosterone.
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with 19-norandrostenedione. Investigational 1,10-Phenanthroline The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with 1,10-Phenanthroline. Experimental Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with 19-norandrostenedione. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with 19-norandrostenedione. Approved, Experimental, Investigational Acetaminophen The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Acetaminophen. Approved Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 19-norandrostenedione. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with 19-norandrostenedione. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with 19-norandrostenedione. Approved, Withdrawn Aldesleukin 19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin. Approved Almasilate The bioavailability of 19-norandrostenedione can be decreased when combined with Almasilate. Approved, Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with 19-norandrostenedione. Experimental Aloglutamol The bioavailability of 19-norandrostenedione can be decreased when combined with Aloglutamol. Approved Aloxiprin The risk or severity of adverse effects can be increased when Aloxiprin is combined with 19-norandrostenedione. Experimental Aluminium The bioavailability of 19-norandrostenedione can be decreased when combined with Aluminium. Approved, Investigational Aluminium acetoacetate The bioavailability of 19-norandrostenedione can be decreased when combined with Aluminium acetoacetate. Experimental Aluminium glycinate The bioavailability of 19-norandrostenedione can be decreased when combined with Aluminium glycinate. Experimental Aluminum hydroxide The bioavailability of 19-norandrostenedione can be decreased when combined with Aluminum hydroxide. Approved, Investigational Ambenonium The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ambenonium. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 19-norandrostenedione. Approved Amiodarone The serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone. Approved, Investigational Amphotericin B 19-norandrostenedione may increase the hypokalemic activities of Amphotericin B. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with 19-norandrostenedione. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with 19-norandrostenedione. Investigational Anthrax immune globulin human The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Anthrax immune globulin human. Approved Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with 19-norandrostenedione. Approved, Investigational Antrafenine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Antrafenine. Approved Apalutamide The serum concentration of 19-norandrostenedione can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with 19-norandrostenedione. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with 19-norandrostenedione. Approved, Investigational Aprepitant The serum concentration of 19-norandrostenedione can be increased when it is combined with Aprepitant. Approved, Investigational Atazanavir The serum concentration of 19-norandrostenedione can be increased when it is combined with Atazanavir. Approved, Investigational Atracurium besylate Atracurium besylate may increase the adverse neuromuscular activities of 19-norandrostenedione. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with 19-norandrostenedione. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with 19-norandrostenedione. Approved Azosemide 19-norandrostenedione may increase the hypokalemic activities of Azosemide. Investigational Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Bacillus calmette-guerin substrain tice live antigen. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with 19-norandrostenedione. Approved, Investigational Bazedoxifene The serum concentration of 19-norandrostenedione can be increased when it is combined with Bazedoxifene. Approved, Investigational BCG vaccine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with BCG vaccine. Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with 19-norandrostenedione. Experimental Bendroflumethiazide 19-norandrostenedione may increase the hypokalemic activities of Bendroflumethiazide. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with 19-norandrostenedione. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with 19-norandrostenedione. Withdrawn Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with 19-norandrostenedione. Approved, Investigational Benzthiazide 19-norandrostenedione may increase the hypokalemic activities of Benzthiazide. Approved Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with 19-norandrostenedione. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with 19-norandrostenedione. Experimental Bismuth subcitrate potassium The bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The bioavailability of 19-norandrostenedione can be decreased when combined with Bismuth subnitrate. Approved Boceprevir The serum concentration of 19-norandrostenedione can be increased when it is combined with Boceprevir. Approved, Withdrawn Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with 19-norandrostenedione. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with 19-norandrostenedione. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with 19-norandrostenedione. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with 19-norandrostenedione. Experimental Bumetanide 19-norandrostenedione may increase the hypokalemic activities of Bumetanide. Approved Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with 19-norandrostenedione. Approved, Nutraceutical Calcium Carbonate The bioavailability of 19-norandrostenedione can be decreased when combined with Calcium Carbonate. Approved, Investigational Calcium silicate The bioavailability of 19-norandrostenedione can be decreased when combined with Calcium silicate. Experimental Capromab pendetide 19-norandrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Capsaicin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Capsaicin. Approved Carbamazepine The serum concentration of 19-norandrostenedione can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with 19-norandrostenedione. Experimental, Investigational Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with 19-norandrostenedione. Approved, Vet Approved, Withdrawn Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with 19-norandrostenedione. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with 19-norandrostenedione. Approved, Investigational Ceritinib 19-norandrostenedione may increase the hyperglycemic activities of Ceritinib. Approved Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with 19-norandrostenedione. Approved, Investigational, Vet Approved Chlorothiazide 19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The serum concentration of 19-norandrostenedione can be increased when it is combined with Chlorotrianisene. Investigational, Withdrawn Chlorphenesin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorthalidone 19-norandrostenedione may increase the hypokalemic activities of Chlorthalidone. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with 19-norandrostenedione. Approved Cimicoxib The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cimicoxib. Investigational Cinoxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ciprofloxacin. Approved, Investigational Cisplatin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Cisplatin. Approved Clarithromycin The serum concentration of 19-norandrostenedione can be increased when it is combined with Clarithromycin. Approved Clodronic Acid The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with 19-norandrostenedione. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Cobicistat The serum concentration of 19-norandrostenedione can be increased when it is combined with Cobicistat. Approved Colesevelam Colesevelam can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens The serum concentration of 19-norandrostenedione can be increased when it is combined with Conjugated estrogens. Approved Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 19-norandrostenedione. Approved Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Coumaphos The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Coumaphos. Vet Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with 19-norandrostenedione. Approved, Investigational Cyclopenthiazide 19-norandrostenedione may increase the hypokalemic activities of Cyclopenthiazide. Experimental Daidzein The serum concentration of 19-norandrostenedione can be increased when it is combined with Daidzein. Experimental Danazol 19-norandrostenedione may increase the fluid retaining activities of Danazol. Approved Darunavir The serum concentration of 19-norandrostenedione can be increased when it is combined with Darunavir. Approved Decamethonium The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Decamethonium. Approved Deferasirox The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Deferasirox. Approved, Investigational Demecarium The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Demecarium. Approved Dersalazine The risk or severity of adverse effects can be increased when Dersalazine is combined with 19-norandrostenedione. Investigational Dexibuprofen The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Dexketoprofen. Approved, Investigational Dichlorvos The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Dichlorvos. Vet Approved Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with 19-norandrostenedione. Approved, Vet Approved Dienestrol The serum concentration of 19-norandrostenedione can be increased when it is combined with Dienestrol. Approved, Investigational Diethylstilbestrol The serum concentration of 19-norandrostenedione can be increased when it is combined with Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with 19-norandrostenedione. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with 19-norandrostenedione. Approved, Investigational Dipivefrin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Dipivefrin. Approved Distigmine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Distigmine. Experimental Donepezil The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Donepezil. Approved Drospirenone The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with 19-norandrostenedione. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with 19-norandrostenedione. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with 19-norandrostenedione. Investigational Echothiophate The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate. Approved Edrophonium The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Edrophonium. Approved Enoxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Enoxacin. Approved, Investigational Enzalutamide The serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide. Approved Epimestrol The serum concentration of 19-norandrostenedione can be increased when it is combined with Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with 19-norandrostenedione. Approved Epitizide 19-norandrostenedione may increase the hypokalemic activities of Epitizide. Experimental Equol The serum concentration of 19-norandrostenedione can be increased when it is combined with Equol. Investigational Estradiol The serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of 19-norandrostenedione can be increased when it is combined with Estradiol valerate. Approved, Investigational, Vet Approved Estriol The serum concentration of 19-norandrostenedione can be increased when it is combined with Estriol. Approved, Investigational, Vet Approved Estrogens, esterified The serum concentration of 19-norandrostenedione can be increased when it is combined with Estrogens, esterified. Approved Estrone The serum concentration of 19-norandrostenedione can be increased when it is combined with Estrone. Approved Etacrynic acid 19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with 19-norandrostenedione. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with 19-norandrostenedione. Experimental Ethinyl Estradiol The serum concentration of 19-norandrostenedione can be increased when it is combined with Ethinyl Estradiol. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with 19-norandrostenedione. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with 19-norandrostenedione. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with 19-norandrostenedione. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with 19-norandrostenedione. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with 19-norandrostenedione. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with 19-norandrostenedione. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with 19-norandrostenedione. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with 19-norandrostenedione. Approved Fenthion The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fenthion. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with 19-norandrostenedione. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with 19-norandrostenedione. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with 19-norandrostenedione. Experimental Fish oil The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fish oil. Approved, Nutraceutical Fleroxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with 19-norandrostenedione. Approved, Withdrawn Flumequine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Flumequine. Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with 19-norandrostenedione. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with 19-norandrostenedione. Experimental Fluoxymesterone 19-norandrostenedione may increase the fluid retaining activities of Fluoxymesterone. Approved, Illicit Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with 19-norandrostenedione. Approved, Investigational Fosaprepitant The serum concentration of 19-norandrostenedione can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of 19-norandrostenedione can be decreased when it is combined with Fosphenytoin. Approved, Investigational Furosemide 19-norandrostenedione may increase the hypokalemic activities of Furosemide. Approved, Vet Approved G17DT The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with G17DT. Investigational Galantamine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Galantamine. Approved Gallamine Triethiodide The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gallamine Triethiodide. Approved Garenoxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gatifloxacin. Approved, Investigational Gemifloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of 19-norandrostenedione can be increased when it is combined with Genistein. Investigational GI-5005 The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with GI-5005. Investigational Ginkgo biloba The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ginkgo biloba. Approved, Investigational, Nutraceutical Ginseng The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ginseng. Approved, Investigational, Nutraceutical GLPG-0492 19-norandrostenedione may increase the fluid retaining activities of GLPG-0492. Investigational Glycerol Phenylbutyrate The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with 19-norandrostenedione. Approved Grepafloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with 19-norandrostenedione. Experimental Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with 19-norandrostenedione. Experimental Hepatitis A Vaccine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Hexestrol The serum concentration of 19-norandrostenedione can be increased when it is combined with Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with 19-norandrostenedione. Investigational Human rabies virus immune globulin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Human rabies virus immune globulin. Approved Huperzine A The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Huperzine A. Approved, Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 19-norandrostenedione. Approved, Investigational Hydrochlorothiazide 19-norandrostenedione may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide 19-norandrostenedione may increase the hypokalemic activities of Hydroflumethiazide. Approved, Investigational Hydrotalcite The bioavailability of 19-norandrostenedione can be decreased when combined with Hydrotalcite. Approved, Experimental, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with 19-norandrostenedione. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with 19-norandrostenedione. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with 19-norandrostenedione. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Icosapent. Approved, Nutraceutical Idelalisib The serum concentration of 19-norandrostenedione can be increased when it is combined with Idelalisib. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with 19-norandrostenedione. Experimental Indacaterol Indacaterol may increase the hypokalemic activities of 19-norandrostenedione. Approved Indapamide 19-norandrostenedione may increase the hypokalemic activities of Indapamide. Approved Indinavir The serum concentration of 19-norandrostenedione can be increased when it is combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with 19-norandrostenedione. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with 19-norandrostenedione. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with 19-norandrostenedione. Withdrawn INGN 201 The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 225. Investigational Ipidacrine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ipidacrine. Experimental Isoflurophate The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Isoflurophate. Approved, Investigational, Withdrawn Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with 19-norandrostenedione. Approved, Investigational Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with 19-norandrostenedione. Withdrawn Itraconazole The serum concentration of 19-norandrostenedione can be increased when it is combined with Itraconazole. Approved, Investigational Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with 19-norandrostenedione. Experimental Ketoconazole The serum concentration of 19-norandrostenedione can be increased when it is combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with 19-norandrostenedione. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with 19-norandrostenedione. Approved Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with 19-norandrostenedione. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with 19-norandrostenedione. Approved, Investigational Levofloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with 19-norandrostenedione. Investigational Lomefloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Lomefloxacin. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with 19-norandrostenedione. Experimental Lopinavir The serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with 19-norandrostenedione. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with 19-norandrostenedione. Approved, Investigational Lumacaftor The serum concentration of 19-norandrostenedione can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with 19-norandrostenedione. Approved, Investigational Magaldrate The bioavailability of 19-norandrostenedione can be decreased when combined with Magaldrate. Approved, Withdrawn Magnesium carbonate The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium carbonate. Approved, Investigational Magnesium hydroxide The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium oxide. Approved Magnesium peroxide The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium peroxide. Experimental Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione. Approved Magnesium silicate The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium silicate. Approved Magnesium Trisilicate The bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Trisilicate. Approved Malathion The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Malathion. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with 19-norandrostenedione. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with 19-norandrostenedione. Approved Mefloquine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Mefloquine. Approved, Investigational Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with 19-norandrostenedione. Approved, Vet Approved Memantine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Memantine. Approved, Investigational Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with 19-norandrostenedione. Approved Mesterolone 19-norandrostenedione may increase the fluid retaining activities of Mesterolone. Experimental Mestranol The serum concentration of 19-norandrostenedione can be increased when it is combined with Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with 19-norandrostenedione. Approved, Investigational, Withdrawn Methallenestril The serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril. Experimental Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Methanesulfonyl Fluoride. Investigational Methyclothiazide 19-norandrostenedione may increase the hypokalemic activities of Methyclothiazide. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Methyl salicylate is combined with 19-norandrostenedione. Approved, Vet Approved Methyltestosterone 19-norandrostenedione may increase the fluid retaining activities of Methyltestosterone. Approved Metoclopramide The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Metoclopramide. Approved, Investigational Metolazone 19-norandrostenedione may increase the hypokalemic activities of Metolazone. Approved Mifepristone The therapeutic efficacy of 19-norandrostenedione can be decreased when used in combination with Mifepristone. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Minaprine. Approved Mitotane The serum concentration of 19-norandrostenedione can be decreased when it is combined with Mitotane. Approved Mivacurium Mivacurium may increase the adverse neuromuscular activities of 19-norandrostenedione. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with 19-norandrostenedione. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with 19-norandrostenedione. Experimental Morniflumate The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Morniflumate. Approved Moxestrol The serum concentration of 19-norandrostenedione can be increased when it is combined with Moxestrol. Experimental Moxifloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Moxifloxacin. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 19-norandrostenedione. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with 19-norandrostenedione. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with 19-norandrostenedione. Approved Nalidixic Acid The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nalidixic Acid. Approved, Investigational Nandrolone 19-norandrostenedione may increase the fluid retaining activities of Nandrolone. Experimental, Investigational Nandrolone decanoate 19-norandrostenedione may increase the fluid retaining activities of Nandrolone decanoate. Approved, Illicit Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with 19-norandrostenedione. Approved, Vet Approved Nefazodone The serum concentration of 19-norandrostenedione can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir. Approved Nemonoxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nemonoxacin. Investigational Neostigmine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Neostigmine. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with 19-norandrostenedione. Approved, Investigational Nevirapine The serum concentration of 19-norandrostenedione can be decreased when it is combined with Nevirapine. Approved Nicorandil The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Nicorandil. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with 19-norandrostenedione. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with 19-norandrostenedione. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with 19-norandrostenedione. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with 19-norandrostenedione. Investigational Norfloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Norfloxacin. Approved Ofloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ofloxacin. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione. Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with 19-norandrostenedione. Vet Approved Oxandrolone 19-norandrostenedione may increase the fluid retaining activities of Oxandrolone. Approved, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with 19-norandrostenedione. Approved Oxolinic acid The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Oxolinic acid. Experimental Oxymetholone 19-norandrostenedione may increase the fluid retaining activities of Oxymetholone. Approved, Illicit Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione. Approved, Withdrawn Palmidrol The risk or severity of adverse effects can be increased when Palmidrol is combined with 19-norandrostenedione. Experimental, Nutraceutical Paraoxon The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Paraoxon. Experimental Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with 19-norandrostenedione. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with 19-norandrostenedione. Approved, Investigational Pazufloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pazufloxacin. Investigational Pefloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pefloxacin. Approved Pentobarbital The serum concentration of 19-norandrostenedione can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Phenobarbital The serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenyl aminosalicylate The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with 19-norandrostenedione. Approved Phenylacetic acid The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with 19-norandrostenedione. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with 19-norandrostenedione. Approved, Vet Approved Phenylbutyric acid The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with 19-norandrostenedione. Approved, Investigational Phenytoin The serum concentration of 19-norandrostenedione can be decreased when it is combined with Phenytoin. Approved, Vet Approved Physostigmine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Physostigmine. Approved, Investigational Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with 19-norandrostenedione. Approved, Investigational Pipemidic acid The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pipemidic acid. Experimental Piretanide 19-norandrostenedione may increase the hypokalemic activities of Piretanide. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with 19-norandrostenedione. Approved, Investigational Piromidic acid The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with 19-norandrostenedione. Experimental Polyestradiol phosphate The serum concentration of 19-norandrostenedione can be increased when it is combined with Polyestradiol phosphate. Approved Polythiazide 19-norandrostenedione may increase the hypokalemic activities of Polythiazide. Approved Pomalidomide The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pomalidomide. Approved Posaconazole The serum concentration of 19-norandrostenedione can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with 19-norandrostenedione. Experimental, Investigational Primidone The serum concentration of 19-norandrostenedione can be decreased when it is combined with Primidone. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with 19-norandrostenedione. Experimental Promestriene The serum concentration of 19-norandrostenedione can be increased when it is combined with Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with 19-norandrostenedione. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with 19-norandrostenedione. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with 19-norandrostenedione. Experimental Prulifloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione. Investigational Pyridostigmine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pyridostigmine. Approved, Investigational Quinestrol The serum concentration of 19-norandrostenedione can be increased when it is combined with Quinestrol. Approved Quinethazone 19-norandrostenedione may increase the hypokalemic activities of Quinethazone. Approved Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rapacuronium Rapacuronium may increase the adverse neuromuscular activities of 19-norandrostenedione. Withdrawn Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione. Approved, Experimental, Investigational Rifabutin The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of 19-norandrostenedione can be decreased when it is combined with Rifapentine. Approved, Investigational Rindopepimut The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rindopepimut. Investigational Rivastigmine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rivastigmine. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with 19-norandrostenedione. Approved, Investigational, Withdrawn Rosoxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rosoxacin. Approved, Investigational Rotavirus Vaccine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rubella virus vaccine. Approved, Investigational Rufloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rufloxacin. Experimental Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with 19-norandrostenedione. Approved, Investigational, Vet Approved Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Salmonella typhi ty21a live antigen. Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with 19-norandrostenedione. Approved Saquinavir The serum concentration of 19-norandrostenedione can be increased when it is combined with Saquinavir. Approved, Investigational Secoisolariciresinol The serum concentration of 19-norandrostenedione can be increased when it is combined with Secoisolariciresinol. Investigational Seliciclib The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with 19-norandrostenedione. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with 19-norandrostenedione. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with 19-norandrostenedione. Investigational Sitafloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sitafloxacin. Experimental, Investigational Sodium bicarbonate The bioavailability of 19-norandrostenedione can be decreased when combined with Sodium bicarbonate. Approved Sparfloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sparfloxacin. Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with SRP 299. Investigational SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with 19-norandrostenedione. Investigational St. John's Wort The serum concentration of 19-norandrostenedione can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stanolone 19-norandrostenedione may increase the fluid retaining activities of Stanolone. Illicit, Investigational Stanozolol 19-norandrostenedione may increase the fluid retaining activities of Stanozolol. Approved, Vet Approved Stiripentol The serum concentration of 19-norandrostenedione can be increased when it is combined with Stiripentol. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with 19-norandrostenedione. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with 19-norandrostenedione. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with 19-norandrostenedione. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with 19-norandrostenedione. Experimental Synthetic Conjugated Estrogens, A The serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of 19-norandrostenedione can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Tacrine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tacrine. Investigational, Withdrawn Talniflumate The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Talniflumate. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with 19-norandrostenedione. Investigational Tecemotide The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tecemotide. Investigational Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with 19-norandrostenedione. Approved, Withdrawn Telithromycin The serum concentration of 19-norandrostenedione can be increased when it is combined with Telithromycin. Approved Temafloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Temafloxacin. Withdrawn Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with 19-norandrostenedione. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with 19-norandrostenedione. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with 19-norandrostenedione. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with 19-norandrostenedione. Approved Testosterone 19-norandrostenedione may increase the fluid retaining activities of Testosterone. Approved, Investigational Testosterone cypionate 19-norandrostenedione may increase the fluid retaining activities of Testosterone cypionate. Approved Testosterone enanthate 19-norandrostenedione may increase the fluid retaining activities of Testosterone enanthate. Approved Testosterone propionate 19-norandrostenedione may increase the fluid retaining activities of Testosterone propionate. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate 19-norandrostenedione may increase the fluid retaining activities of Testosterone undecanoate. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with TG4010. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 19-norandrostenedione. Approved Tibolone The serum concentration of 19-norandrostenedione can be increased when it is combined with Tibolone. Approved, Investigational Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with 19-norandrostenedione. Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 19-norandrostenedione. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with 19-norandrostenedione. Approved Torasemide 19-norandrostenedione may increase the hypokalemic activities of Torasemide. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with 19-norandrostenedione. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Triamcinolone. Approved, Vet Approved Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with 19-norandrostenedione. Experimental Trichlorfon The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trichlorfon. Vet Approved Trichlormethiazide 19-norandrostenedione may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with 19-norandrostenedione. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with 19-norandrostenedione. Approved Tromethamine The bioavailability of 19-norandrostenedione can be decreased when combined with Tromethamine. Approved Trovafloxacin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Trovafloxacin. Approved, Investigational, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tubocurarine. Approved Typhoid Vaccine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Typhoid Vaccine. Approved Tyrothricin The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Tyrothricin. Approved Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with 19-norandrostenedione. Approved, Investigational, Withdrawn Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Voriconazole The serum concentration of 19-norandrostenedione can be increased when it is combined with Voriconazole. Approved, Investigational Warfarin 19-norandrostenedione may increase the anticoagulant activities of Warfarin. Approved Yellow Fever Vaccine The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Yellow Fever Vaccine. Approved, Investigational Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with 19-norandrostenedione. Approved, Investigational Zeranol The serum concentration of 19-norandrostenedione can be increased when it is combined with Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with 19-norandrostenedione. Approved, Investigational, Withdrawn Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with 19-norandrostenedione. Withdrawn - Food Interactions
- Not Available
References
- General References
- Diel P, Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schanzer W, Schleipen B, Thevis M, Vollmer G, Zierau O: The prohormone 19-norandrostenedione displays selective androgen receptor modulator (SARM) like properties after subcutaneous administration. Toxicol Lett. 2008 Apr 1;177(3):198-204. doi: 10.1016/j.toxlet.2008.01.014. Epub 2008 Feb 2. [PubMed:18325697]
- External Links
- KEGG Compound
- C14500
- PubChem Compound
- 92834
- PubChem Substance
- 46505377
- ChemSpider
- 83803
- ChEBI
- 34187
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- 19-Norandrostenedione
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0454 mg/mL ALOGPS logP 2.53 ALOGPS logP 3.63 ChemAxon logS -3.8 ALOGPS pKa (Strongest Acidic) 19.19 ChemAxon pKa (Strongest Basic) -4.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 34.14 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 79.13 m3·mol-1 ChemAxon Polarizability 31.54 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9723 Caco-2 permeable + 0.7785 P-glycoprotein substrate Substrate 0.5551 P-glycoprotein inhibitor I Inhibitor 0.8097 P-glycoprotein inhibitor II Non-inhibitor 0.6972 Renal organic cation transporter Non-inhibitor 0.638 CYP450 2C9 substrate Non-substrate 0.827 CYP450 2D6 substrate Non-substrate 0.9064 CYP450 3A4 substrate Substrate 0.6816 CYP450 1A2 substrate Non-inhibitor 0.8259 CYP450 2C9 inhibitor Non-inhibitor 0.9269 CYP450 2D6 inhibitor Non-inhibitor 0.94 CYP450 2C19 inhibitor Non-inhibitor 0.7094 CYP450 3A4 inhibitor Non-inhibitor 0.8652 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7931 Ames test Non AMES toxic 0.9189 Carcinogenicity Non-carcinogens 0.9403 Biodegradation Not ready biodegradable 0.9401 Rat acute toxicity 1.6104 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7011 hERG inhibition (predictor II) Non-inhibitor 0.7574
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key GC-MS Spectrum - EI-B GC-MS splash10-00di-2950000000-5865fd40ca280de239b7 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Estrane steroids
- Direct Parent
- Estrogens and derivatives
- Alternative Parents
- 3-oxo delta-4-steroids / 17-oxosteroids / Delta-4-steroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
- Substituents
- Estrogen-skeleton / Oxosteroid / 17-oxosteroid / 3-oxosteroid / 3-oxo-delta-4-steroid / Delta-4-steroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 3-oxo steroid (CHEBI:34187)
Drug created on July 24, 2007 14:36 / Updated on July 02, 2018 17:33